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Gastrointestinal ﬂuid is a complexmilieu and it is recognised that gut drug solubility is different to that observed
in simple aqueous buffers. Simulated gastrointestinal media have been developed covering fasted and fed states
to facilitate in vitro prediction of gut solubility and product dissolution. However, the combination of bile salts,
phospholipids, fatty acids and proteins in an aqueous buffered system createsmultiple phases and drug solubility
is therefore a complex interaction between these components, which may create unique environments for each
API. The impact on solubility can be assessed through a statistical design of experiment (DoE) approach, to deter-
mine the inﬂuence and relationships between factors. In this paperDoE has been applied to fed simulated gastro-
intestinal media consisting of eight components (pH, bile salt, lecithin, sodium oleate, monoglyceride, buffer, salt
and pancreatin) using a two level D-optimal design with forty-four duplicate measurements and four centre
points. The equilibrium solubility of a range of poorly soluble acidic (indomethacin, ibuprofen, phenytoin,
valsartan, zaﬁrlukast), basic (aprepitant, carvedilol, tadalaﬁl, bromocriptine) and neutral (fenoﬁbrate, felodipine,
probucol, itraconazole) drugs was investigated. Results indicate that the DoE provides equilibrium solubility
values that are comparable to literature results for other simulated fed gastrointestinal media systems or
human intestinal ﬂuid samples. For acidic drugs the inﬂuence of pH predominates but other signiﬁcant factors
related to oleate and bile salt or interactions between them are present. For basic drugs pH, oleate and bile salt
have equal signiﬁcance along with interactions between pH and oleate and lecithin and oleate. Neutral drugs
show diverse effects of the media components particularly with regard to oleate, bile salt, pH and lecithin but
the presence of monoglyceride, pancreatin and buffer have signiﬁcant but smaller effects on solubility. There
are fourteen signiﬁcant interactions between factors mainly related to the surfactant components and pH, indi-
cating that the solubility of neutral drugs in fed simulated media is complex. The results also indicate that the
equilibrium solubility of each drug can exhibit individualistic behaviour associated with the drug's chemical
structure, physicochemical properties and interactionwithmedia components. The utility of DoE for fed simulat-
ed media has been demonstrated providing equilibrium solubility values comparable with similar in vitro sys-
tems whilst also providing greater information on the inﬂuence of media factors and their interactions. The
determination of a drug's gastrointestinal solubility envelope provides useful limits that can potentially be ap-
plied to in silico modelling and in vivo experiments.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The current trend in drugdiscovery towardsmoleculeswith a higher
molecular weight and increased lipophilicity continues to result in a
greater number of drug candidates with decreasing aqueous solubility
(Sugano et al., 2007), (Lipinski, 2000). Aqueous solubility is a key pa-
rameter inﬂuencing biological activity (Stegemann et al., 2007),
formulation (Pouton, 2006) and in vitro and in vivo biopharmaceutical
performance (Lipinski, 2000). Aqueous solubility may be determined
in vitro using a number of experimental techniques (Sugano et al.,
2007). Intrinsic solubility is a measure of the neutral (non-ionised)
molecule's maximum solubility (Yalkowsky, 1999) in aqueous solution,
whilst equilibrium solubility includes both un-ionised and ionised
forms using a deﬁned aqueous system (pH and presence of other
salts) and employing the drug's most stable solid form in contact with
the solution. Either value can be measured using classical shake-ﬂask
methods (Dittert et al., 1964) where an excess of solid drug is mixed
with a buffered solution phase until equilibrium is achieved. During
oral administration and absorption, an equilibrium concentration is un-
likely to exist due to the competing processes of dissolution and
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absorption although equilibrium aqueous solubility is demonstrably
still a key parameter controlling rate and extent of absorption (Sugano
and Terada, 2015). This is recognised in theBiopharmaceutics Classiﬁca-
tion System where drugs are allocated to categories based on solubility
with respect to dose either high or low and gastrointestinal permeabil-
ity (Amidon et al., 1995). Low solubility drugs present problems during
formulation and development (Butler and Dressman, 2010) and in
order to avoid solubility related failures during drug discovery, an
early and comprehensive assessment of a drug's solubility is essential
(Bergstrom et al., 2014).
Peroral drug administration is the most convenient and popular
method for drug therapy covering a range of diseases and applications
from acute through to chronic dosing. The normal function of the gas-
trointestinal tract is to provide efﬁcient nutrition from a range of food
matrices, coupled with excretion of metabolic waste products. This is
accomplished by a dynamic, responsive secretion of ﬂuids, and appro-
priate muscular activity to mix food, extract nutrients with the residues
being pushed forward. It is appreciated therefore that the dynamic and
complex physiology of the gastrointestinal tract inﬂuences drug absorp-
tion (Varum et al., 2013). Twomajor features of the gut are the inherent
physicochemical conditions within the tract which vary with position
along the tract (Bergstrom et al., 2014;Mudie et al., 2010) and the effect
of ingested food (Yasuji et al., 2012) on these conditions, both of which
exhibit intra- and inter-subject variability. Simple aqueous drug solubil-
ity therefore cannot reﬂect gastrointestinal solubility (Dressman et al.,
2007) and in order to improve this determination in vitro, either sam-
pled human ﬂuids can be employed (Augustijns et al., 2014) or simulat-
ed gastrointestinal media prepared (Vertzoni et al., 2004). Human
gastrointestinal ﬂuids are expensive and problematical to sample, vari-
able in composition (Bergstrom et al., 2014; Riethorst et al., 2016), un-
stable in air and therefore not an ideal material for in vitro
experimental studies. Simulated gastrointestinal media are more easily
prepared and two initial recipes simulating the fed statewere published
in 1998 (Dressman et al., 1998;Galia et al., 1998) see Table 1. Several ad-
aptations have been investigated, for example changing the buffer to
citrate (Vertzoni et al., 2004) or maleate (Jantratid et al., 2008a) and
modiﬁcation of the bile salt and lecithin concentration and ratio plus
the inclusion of additional components such as monoglyceride or fatty
acid (Jantratid et al., 2008b; Kleberg et al., 2010). However, a ﬁxed
composition simulated media reﬂects a single physicochemical state
usually based around the average of measured parameters. As already
discussed, gastrointestinal ﬂuid composition is highly variable
(Riethorst et al., 2016) and the situation is further confounded by
changes in ﬂuid composition as the mass passes along the small intes-
tine (Bergstrom et al., 2014).
In order to investigate the inﬂuence of simulated fasted gastrointes-
tinal media composition on the equilibrium solubility of twelve test
drugs (four acidic, four basic and four neutral), we have employed a de-
sign of experiment (DoE) (Myers et al., 2009) type approach using pub-
lished literature composition values for fasted gastrointestinal ﬂuid
(Khadra et al., 2015). This study illustrated that the DoE approach was
feasible, simulated the inherent solubility variability associated with
fasted gastrointestinal ﬂuid and identiﬁed the key media components
controlling solubility. For acidic drugs, pH was the major factor, whilst
for basic and neutral compounds a combination of pH and the concen-
trations of fatty acid, bile salt and lecithin were important. The DoE
also highlighted interactions between media components, for example
pH and fatty acid, an interdependence that would otherwise have
been undetected and also identiﬁed drugs where solubility behaviour
was unusual or inﬂuenced by media components or interactions.
In this paper we have extended the DoE approach (Khadra et al.,
2015) to simulated fed gastrointestinal media using the same compo-
nents at higher concentrations and with the addition of monoglyceride
as an additional fed media component, Table 1 (Jantratid et al., 2008a;
Kleberg et al., 2010). The lower and upper concentration values of the
experiment are presented in Table 2 and are based on published mea-
sured fed intestinal ﬂuid ranges as reviewed by Bergstrom and col-
leagues (Bergstrom et al., 2014) (see Figs. 1, 6, 9 and 10) and typical
concentrations employed by previously published simulated fed
media, see Table 1. The addition of a factor to a fractional factorial DoE
would double the number of required test conditions if the power of
the experiment was to remain constant. In order to limit the number
of conditions tested, the experimental design has been changed to a
D-optimal design, which accommodates the same number of factors
with less experiments. The D-optimal design provides an increased res-
olution of themain effects but with a reduced resolution of twoway in-
teractions. Finally, the HPLC method has been simpliﬁed to a single
method accommodating all tested drugs.
2. Materials and methods
2.1. Materials
Hydrochloric acid (HCl), potassiumhydroxide (KOH), acetic acid, so-
dium taurocholate, lecithin S PC (phosphatidylcholine from Soybean
“98%”) from Lipoid, Germany and Pancreatin from porcine sources,
monosodium phosphate (NaH2PO4), sodium chloride (NaCl), chloro-
form, fenoﬁbrate, and indomethacin were purchased from Sigma-
Aldrich, Poole, Dorset UK. The active pharmaceutical ingredients
aprepitant, carvedilol, felodipine, probucol, tadalaﬁl and zaﬁrlukast
were kindly provided through OrBiTo (see Acknowledgements) by Dr.
R. HolmHead of Preformulation, Lundbeck, Denmark. Itraconazole, bro-
mocriptine, valsartan andphenytoinwere purchased fromSigma, Poole,
Dorset, UK. Sodium oleate was obtained from BDH Chemical Ltd. Poole
England. All water used was ultrapure Milli-Q water. The analytical sol-
vents methanol and acetonitrile were of HPLC grade (VWR, UK). Other
materials used in this study included triﬂuoroacetic acid (Merck
Schuchardt OHG, Germany) and ammoniumacetate (Merck, Germany).
2.2. Design of experiment and data analysis
A D-Optimal DoE with 8 factors (either a component concentration
or a system parameter such as pH) and 2 levels was constructed and
analysed usingMODDE (Umetrics) with the design selected using G-ef-
ﬁciency, which required 92 different experiments (44 conditions each
measured in duplicate and 4 repeating centre points). Two assumptions
Table 1
Composition of literature fed simulated intestinal media (FeSSIF).
Dressman et al., 1998
(FeSSIF)
Galia et al., 1998
(FeSSIF) Vertzoni et al., 2004
Jantratid et al., 2008a
(FeSSIF-V2) Kleberg et al., 2010
pH 5 5 5 5.8 6.5
Buffer Acetate Acetate Citrate Maleate Maleate
Sodium taurocholate 15 mM 15 mM 15 mM 10 mM 5–20 mM
Lecithin 4 mM 3.75 mM 3.75 mM 2 mM 1.25–5 mM
BS/PL 3.75 4 4 5 4
Salt 0.19 M (KCl) 0.20 M (KCl)
Sodium oleate – – – 0.8 mM 0–45 mM
Mono-oleate – – – 5 mM 0–10 mM
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were made when designing and analysing the DoE. First, only main ef-
fects and 2-way interactions (quadratic terms) are included in the
model, and 3-way (ormore) interactionswere not determined. Second-
ly, it was proposed that the main effect can be positive (+) or negative
(−), but when it is involved in interaction, the conclusion will be con-
sidered with the interactions (±).
2.3. Equilibrium solubility measurements
2.3.1. Preparation of lipid stock solutions
Sodium taurocholate, lecithin ormonoglyceridewereweighed into a
ﬂask and 1 to 2 mL of chloroform added and mixed to dissolve all the
solid material. Chloroform was removed in a stream of nitrogen gas to
ensure a dry ﬁlm was produced. Water (3 mL) was added to reconsti-
tute the dried ﬁlm, stirred to prepare a homogeneous mixture and
transferred to a 5 mL volumetric ﬂask and made to volume with water.
2.3.2. Preparation of aqueous stock solutions
Salt Stock Solution: Sodium chloride (4.45 g) was weighed into a
25 mL volumetric ﬂask, dissolved and made up to volume with water.
Buffer Stock Solution:Maleic acid (5.05 g)wasweighed into a 50mL
volumetric ﬂask in duplicate, dissolved in water 40 mL approx., the pH
of each ﬂask adjusted to 5 (Maleic buffer A) or 7 (Maleic buffer B)
using 0.5 M HCl or 0.5 M KOH and made up to volume with water.
Sodium Oleate Stock Solution: Sodium oleate (3.81 g) was weighed
into a 50 mL volumetric ﬂask, dissolved in water under gentle heat
and made to ﬁnal volume. Solution was then kept at 50 °C to aid
solubilisation.
Pancreatin Stock Solution: Pancreatin (2.86 g) was weighed in to a
20 mL volumetric ﬂask, dissolved and made up to volume with water.
2.3.3. Preparation of measurement solutions
The concentration of each stock solution was designed to be 15
times greater than the high concentration value required for the DoE,
with the exception of sodium oleate where only a 5 times concentrate
was possible. The stock solutions lipid and aqueous were combined in
the preparation of the ﬁnal DOE experimental solutions to provide the
44 conditions required by the model.
2.3.4. Determination of equilibrium solubility
Aweight of powdered drug greater than its estimated solubility (cal-
culated from literature solubility values in FESSIF or HIF if available)was
added to each 15 mL centrifuge tube (92 in total). The required amount
of each stock solution (section above) andwaterwas added to each tube
to provide aﬁnal volumeof 4mL and thepHwas adjusted to 5 or 7 using
0.5MHCl or 0.5MKOH. Tubeswere shaken for 1 h at room temperature
and examined for the presence of solid drug. If no solid drug was seen a
further quantity of solid drug was added and above steps repeated.
Tubes were then placed in an orbital shaker and incubated for 24 h at
37 °C and 240 rpm. Following incubation the pH of the tube was mea-
sured. Tubes were then centrifuged (10,000 rpm, 15 min) and 500 μL
of supernatant was removed for solubilised drug concentration
determination by HPLC. The supernatant was measured directly and
not treated any further.
2.4. HPLC concentration measurement
HPLCwas performed using an Agilent Technologies 1260 Series Liq-
uid Chromatography systemcontrolled byClarity Chromatography soft-
ware. Mobile Phase: A: 10 mM Ammonium formate pH 3.0 in water; B:
10 mM Ammonium formate pH 3.0 in MeCN/H2O (9:1 v/v), Flow rate
1.5 mL/min, Gradient: Time 0, 70%A:30%B, 3 min 0%A:100%B, 4 min
0%A:100%B, 4.5 min 70%A:30%B total run time 10 min; Column: ACE
3 μmC18,: 50 × 3.0mm, Column Temperature: 60 °C, Injection volume:
10 μL, Detection: 214 nm.
3. Results and discussion
3.1. Equilibrium solubility measurements
The results for the individual equilibrium solubility measurements
in each DoE experiment are presented in Fig. 1. For each drug variability
is evident,which in some cases is up to three orders ofmagnitude. In ad-
dition, for several drugs very low solubility determinationswere record-
ed for multiple media recipes. Literature equilibrium solubility values
(where available) (Augustijns et al., 2014) in either HIF or fed simulated
gastrointestinal media are superimposed on Fig. 1 and lie within the
DoE values. It is interesting to note that although all the values liewithin
the solubility rangemeasured, theHIF values are at the higher end of the
range compared to the simulatedmedia values. Overall the range of sol-
ubility values reported in Fig. 1 are higher than those for a fasted DoE
(Khadra et al., 2015) an outcome that is in agreementwith literature re-
sults for solubility differences between the fasted and fed states
(Augustijns et al., 2014; Bevernage et al., 2010; Clarysse et al., 2011).
The variability in solubility is drugdependent andmirrors literature var-
iability values; for example, felodipine shows a greater variability than
fenoﬁbrate (Augustijns et al., 2014). However, the DoE may overesti-
mate variability due to the statistical analysis of factor combinations
that are not biorelevant. In addition the phase behaviour and emulsion
homogeneity of each DoE point was not assessed and this also has the
potential to inﬂuence solubility. The effect of the two level DoE, espe-
cially with respect to pH and inﬂuence on acidic drug solubility is not
as evident as in a published fasted DoE (Khadra et al., 2015). The mea-
sured equilibrium solubility values indicate that the DoE covered the
Table 2
Composition and concentration levels employed in design of experiment for fed simulated
intestinal media.
Parameter Substance Lower limit Upper limit
Bile salt (mM) Sodium TC 3.6 24
Lecithin (mM) Egg PL 0.5 4.8
Buffer (mM) Maleic acid 28.6 58.09
Salt (mM) NaCl 125 203
pH NaOH/HCl 5 7
Enzyme (U/ml) Pancreatin 100 150
Fatty acid (mM) Sodium oleate 0.8 52
Monoglyceride Glycerylmonooleate 1 6.5
TC: taurocholate, PL: phosphatidylcholine.
Fig. 1. Design of experiment equilibrium solubility measurements. Equilibrium solubility
measurements for each drug (acidic red coloured points; basic blue coloured points;
neutral yellow coloured points) based on media compositions detailed in Table 2. ○
reported solubility values for individual drugs in FeSSIF, ∇ reported solubility values for
individual drugs in fed HIF, all values from (Augustijns et al., 2014).
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appropriate solubility space and mirrored the variability previously de-
termined using alternative media systems.
3.2. Solubility inﬂuence of individual DoE factors
The individual media components standardised effect on the mea-
sured equilibrium solubility of each drug was calculated, see Fig. 2.
Each drug exhibits a different proﬁle indicating the complex nature of
the interactions between drug and individual media components. The
components with the lowest overall inﬂuence on solubility are salt (1
signiﬁcant result from 13 drugs), buffer and monoglyceride (2 from
13), and pancreatin (3 from 13). The componentswith the biggest over-
all inﬂuence on solubility are bile salt (12 signiﬁcant results from 13
drugs) followed by pH, oleate and lecithin (10 from 13). This is compa-
rable to the published fasted DoEwhere pancreatin was the component
with the least number of signiﬁcant inﬂuences (1 from 12 drugs)
followed by salt (5 from 12 drugs) (Khadra et al., 2015). The mean of
the absolute standardised effect value grouped for acidic, basic and neu-
tral drugs is presented in Fig. 3, this provides information on a factor's
overallmagnitude of inﬂuencebutmasks the effect direction if it is to in-
crease or decrease solubility.
For acidic drugs the componentwith the biggestmagnitude of effect
is pH, which is identical to the reported fasted DoE (Khadra et al., 2015)
but the value is reduced from ninety to around ﬁfteen. This may be re-
lated to the increased concentration and therefore solubilising capacity
of the “surfactant” components present in this system. For all drugs the
Fig. 2. Standardised effect values for individual doe factors on equilibrium solubility. DoE standardised effect values (x-axis) for individual factors (as listed in ﬁgure titles) on equilibrium
solubility. Vertical hatched black lines indicate statistical signiﬁcance (P b 0.05), bar direction indicates direction of effect, to the right of 0 on x-axis is a positive effect on solubility, bar
length indicates the magnitude of the effect. Acidic drugs red coloured bars; Basic blue coloured bars; Neutral yellow coloured bars.
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effect is positive, which is identical to the previously reported inﬂuence
of HIF pH on the solubility of acidic drugs (Clarysse et al., 2009) where
for indomethacin this accounted for around 90% of the measured solu-
bility effect. The effects of oleate, bile salt and lecithin concentrations
are also generally signiﬁcant (Fig. 3) but the effect is variable between
the drugs (Fig. 2). Bile salt positively affects indomethacin, phenytoin
and ibuprofen and negatively valsartan, whilst oleate and lecithin only
positively affects indomethacin, zaﬁrlukast and phenytoin. The interac-
tion of bile salt components such as cholic acid with indomethacin has
been shown to occur through the hydrophobic domains of both mole-
cules to form the core of amixedmicelle (Prakash et al., 2012). The pos-
itive inﬂuence of bile salt and phospholipid on indomethacin solubility
in HIF has also been previously reported, accounting for approximately
10% of the solubility effect (Clarysse et al., 2009). The remaining compo-
nents have no signiﬁcant impact on acidic drug solubility with the ex-
ception of a single result for pancreatin on phenytoin.
For basic drugs the inﬂuence of pH is not as dominant when com-
pared to the acidic and a more complicated pattern is evident (see
Figs. 2 and 3) with pH, oleate and bile salt exhibiting similar effect
values with lecithin just signiﬁcant. In the majority of examples (eight
out of twelve, Fig. 2) oleate, bile salt and lecithin exhibit a positive effect
on solubility indicating the importance of the surfactant components
with some notable negative solubility effects of oleate and bile salt
with bromocriptine and lecithin with aprepitant. Monoglyceride, salt,
buffer and pancreatin do not inﬂuence basic drug solubility with only
two out of a possible twenty producing signiﬁcant effects, pancreatin
with aprepitant and carvedilol with buffer.
For neutral drugs, the number of signiﬁcant factors is even greater
with oleate and bile salt showing dominant effects, followed by lecithin
and pH with monoglyceride, buffer and pancreatin registering average
values that are signiﬁcant. Oleate, lecithin and bile salt (with the excep-
tion of bile salt with fenoﬁbrate) have a positive inﬂuence on solubility
indicating the importance of the surfactant components for this group
of drugs. Surprisingly the effect of monoglyceride is mixed, a result at-
tributable to a positive effect on probucol and fenoﬁbrate offset by a
negative effect on felodipine. Whilst the absolute average effect of pH
on neutral drugs is signiﬁcant, Fig. 2 indicates that the solubility effect
can be positive or negative. Since in these cases pH cannot inﬂuence
drug ionisation, this effect is mediated through ionisation of the other
media components in a similar manner to that noted in the fasted DoE
(Khadra et al., 2015).
The multi-component inﬂuences on the solubility of neutral and
basic drugs in HIF has been previously reported (Clarysse et al., 2009)
and these results are also in agreement with the fasted DoE ﬁndings
(Khadra et al., 2015) for these drug categories. This emphasises the im-
portance of the solubilising capacity of the media (Ilardia-Arana et al.,
2006) and the inﬂuence of pH on the solubility of neutral drugs in
these systems (Pedersen et al., 2000) acting through ionisation of the
solubilising components. It is interesting to note that mono-glyceride,
which is included in fed simulated media (Jantratid et al., 2008b;
Kleberg et al., 2010) only inﬂuenced the solubility of two neutral
drugs, fenoﬁbrate and probucol, a result that is similar to literature re-
ports (Kleberg et al., 2010) of oleic acid and monoolein, increasing the
solubility of fenoﬁbrate and cinnarizine with limited inﬂuence on gris-
eofulvin or danazol.
3.3. Solubility inﬂuence of DoE factor combinations
The DoE provides information on the standardised effect values of
interactions between factors on drug solubility and the results are pre-
sented in Figs. 4a and 4b with average absolute values in Fig. 5. Where
an interaction occurs it generally has a lower standardised effect than
one of the single factors on its own and there are a greater number of
signiﬁcant interactions for the neutral compounds than either acids or
bases, see Fig. 5. Interactions have been separated into two groups
based on the statistical signiﬁcance of the average absolute standardised
effect value with the neutral compound interactions employed since it
is the largest set. A comparison with factor interactions in the fasted
DoE is possible but should be treated with caution since several interac-
tions were confounded in these published results (Khadra et al., 2015)
and the statistical methods employed are different.
3.3.1. Solubility inﬂuence of statistically signiﬁcant DoE factor combinations
For acidic compounds the only two signiﬁcant interactions involve
pH with either oleate or bile salt, whose pKa's are respectively 5.0 and
between 4.5 and 6.5 (Holm et al., 2013). For aqueous fatty acid systems
for example it is reported that pH7 represents a phase change boundary
(Cistola et al., 1988) and the aggregation and surface tension properties
of bile salts are also pH dependent (Fernández-Leyes et al., 2008). A sig-
niﬁcant interaction between pH and either oleate or bile salt is therefore
to be expected since their ionisation will vary in the DoE pH range and
the results indicate that this inﬂuences solubilisation. Based on litera-
ture results this is probably also linked to changes in the systems
phase behaviour (Elvang et al., 2016) however it is interesting that the
DoE does not register a signiﬁcant interaction between bile salt and ole-
ate for the acidic drugs. No other factor combinations produced a statis-
tically signiﬁcant average value but for individual drugs statistically
signiﬁcant events are present. The interaction between bile salt and lec-
ithin for example is not on average signiﬁcant however a signiﬁcant ef-
fect is noted for valsartan (Fig. 4a) but no other drugs. It has been
previously reported that the combination of bile salt and lecithin in
HIF inﬂuenced the solublity of indomethacin (Clarysse et al., 2009) at
around one tenth of themagnitude of the pH effect. In this study the in-
teraction between these factors on indomethacin solubilitywas positive
at around 1 but not statistically signiﬁcant (Fig. 4a) with the effect of pH
measured at 27, a ratio that is similar to the reported HIF result. The two
signiﬁcant interactions are identical to those reported for the fasted DoE
(Khadra et al., 2015) for acids but the signiﬁcant interaction between
buffer and pH noted in the fasted setting was not replicated in the fed.
For basic drugs the average standardised effect values for the interac-
tions between pH and oleate and lecithin and oleate are signiﬁcant, and
similar comments to those for the acids above with respect to pH apply.
However, since lecithin ionisation is not inﬂuenced by pH thismay repre-
sent a threeway (or greater) interactionwith pH inﬂuencing an ionisable
component, for example oleate, which in turn interacts with the lecithin.
For practical reasons related to the number of experiments the DoE is not
powered to examine this type of relationship. There are occasional signif-
icant interactions for other factors with individual drugs, for example a
negative solubility effect of lecithin and oleate with aprepitant and a pos-
itive effect of bile salt andmonoglyceridewith carvedilol. However, there
is no obvious consistent pattern with these interactions, which indicates
that they may arise through the drugs structural and physicochemical
properties (Kleberg et al., 2010). For nifedipine and ketoconazole pH,
fatty acids and the combination of bile salt and phospholipids have
been shown to inﬂuence solubility (Clarysse et al., 2009) but interactions
between the factorswas not determined. Similar to the acidic compounds
Fig. 3. Average absolute standardised effect values grouped by drug category. Average
value of the absolute standardised effect for each factor grouped by drug category, note
that this removes direction of effect information. Horizontal hatched black line indicates
statistical signiﬁcance (P b 0.05). Acidic drugs red coloured bars; Basic blue coloured
bars; Neutral yellow coloured bars.
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the number of signiﬁcant interactions in the fed DoE is fewer than the
fasted DoE (Khadra et al., 2015) with only pH and oleate signiﬁcant in
both cases. None of the other twenty six possible interactionswere signif-
icant for the basic drugs.
For neutral drugs the pattern of factor interactions is more complicat-
ed with ﬁfteen signiﬁcant results based on the average absolute
standardised effect values, providing in some cases (for example pH
with oleate) effect values comparable with the single factor result, see
Figs. 4a and 5. The most frequent factors involved in signiﬁcant interac-
tions are buffer and lecithin in ﬁve interactions each followed by oleate,
bile salt, monoglyceride and pH in four and salt and pancreatin in two.
The average standardised effect value removes information on the
direction of the effect and Fig. 4a emphasises the complex nature of the
solubility pattern. For example, the interaction between bile salt and ole-
ate or lecithin results in a solubility increase for all the neutral drugs,
which is in line with literature results for these components (Soderlind
et al., 2010). However, pH and oleate interact to increase the solubility
of felodipine and fenoﬁbrate but decrease the solubility of itraconazole
and probucol, indicating that in some cases the drug's molecular proper-
ties are inﬂuencing the outcome. Generally, the interactions between the
surfactant components (bile salt, lecithin, oleate and monoglyceride) act
to increase solubility, with a few exceptions, whilst those involving buffer
and salt tend to decrease solubility, with the effect of the remaining inter-
actions being variable. This pattern is similar to the results from the fasted
Fig. 4a. Standardised effect values for doe factor interactions on equilibrium solubility. DoE standardised effect values (x-axis) for individual factors (as listed inﬁgure titles) on equilibrium
solubility. Vertical hatched black lines indicate statistical signiﬁcance (P b 0.05), bar direction indicates direction of effect, to the right of 0 on x-axis is a positive effect on solubility, bar
length indicates the magnitude of the effect. Interactions which provide a statistically signiﬁcant average absolute standardised effect value included. Abbreviations; Pan - pancreatin;
Mono –monoglyceride. Acidic drugs red coloured bars; Basic blue coloured bars; Neutral yellow coloured bars.
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media DoE (Khadra et al., 2015) where the bile salt, lecithin interaction
had a uniformly positive effect on solubilitywhilst pH and oleatewas var-
iable. Overall these results indicate that for neutral drugs solubility in sim-
ulated fed media is a complex phenomenon that will be dependent on
the ratio of multiple components and the interactions between them
(Birru et al., 2014; Kleberg et al., 2010).
3.3.2. Solubility inﬂuence of statistically non-signiﬁcant DoE factor
combinations
The factor interactionswhere the average absolute standardised effect
value was not statistically signiﬁcant for neutral drugs are presented in
Fig. 4b. Note that this is based on the neutral drugs where thirteen of
the possible twenty eight interactions are non-signiﬁcant a value that is
lower than the acidic or basic drugs where twenty six of twenty eight in-
teractions are non-signiﬁcant. Based on the neutral drugs the most fre-
quently non-signiﬁcant factor interactions at ﬁve times each are
pancreatin and salt a similar pattern to the fasted DoE (Khadra et al.,
2015). The remaining factors occur with roughly equal frequency and
only one interaction between surfactant components, oleate withmono-
glyceride, is present. However, it should be noted that even though the
interaction ranking is based on the absolute average standardised effect
value, signiﬁcant effects on individual drugs are still present, for example
bile salt with buffer or pancreatin has a positive effect on the solubility of
indomethacin.
Fig. 4b. Standardised effect values for doe factor interactions on equilibrium solubility. DoE standardised effect values (x-axis) for individual factors (as listed inﬁgure titles) on equilibrium
solubility. Vertical hatched black lines indicate statistical signiﬁcance (P b 0.05), bar direction indicates direction of effect, to the right of 0 on x-axis is a positive effect on solubility, bar
length indicates the magnitude of the effect. Interactions which do not provide a statistically signiﬁcant average absolute standardised effect value included. Acidic drugs red coloured
bars; Basic blue coloured bars; Neutral yellow coloured bars.
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3.4. Combined factors and factor interactions
The DoE consisted of eight factors and a possible twenty eight inter-
actions between the factors and the ranked average absolute
standardised effect value for each group of drugs is presented in Fig. 5.
This illustrates the difference in the impact of the various factors and
factor interactions for the three drug categories. Acidic drug solubility
is inﬂuenced by pH, oleate and bile salt or by interactions between
these factors,with the inﬂuence of pHdominant. The remainingﬁve fac-
tors and twenty six interactions are not signiﬁcant. This is similar to the
fasted DoE (Khadra et al., 2015) with the exception that buffer and lec-
ithin were also signiﬁcant. For basic drugs pH, oleate, bile salt and leci-
thin as individual factors are signiﬁcant along with interactions
between pH and oleate and lecithin and oleate. The remaining four fac-
tors and twenty six interactions are not signiﬁcant. In a similar manner
to the acids this is a smaller number when compared to the fasted DoE
where buffer and salt as single factors along with interactions between
bile salt and oleate, lecithin and salt, bile salt and buffer, lecithin and pH
and salt and pHwere signiﬁcant. In both acids and bases this difference,
as discussed above, may represent a dominance of the surfactant based
components due to their higher concentration in the fed state. For neu-
tral compounds a more complicated picture is evident with only salt as
single factor not signiﬁcant and ﬁfteen of the possible twenty six inter-
actions signiﬁcant. This is similar to the fasted DoE where only pancre-
atinwas non-signiﬁcant as a single factor. The interactionswhich are no
longer signiﬁcant when comparing the fasted and fed DoEs are salt and
pH, lecithin and salt, oleate and salt and bile salt and buffer, again this
may represent a dominance of the surfactant based components due
to their higher concentration in the fed state. Although it should be
noted that the handling of factor interactions differs in each DoEs.
Fig. 5.Average absolute standardised effect values for factors and factor interactions grouped by drug category. Average value of the absolute standardised effect for each factor and factor
interaction grouped by drug category, note that this removes direction of effect information. Horizontal hatched black line indicates statistical signiﬁcance (P b 0.05).
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Overall the results indicate that the solubilisation of neutral compounds
in fed simulated intestinal media is a complex relationship contributed
to by the individual factors and numerous interactions (Clarysse et al.,
2009; Kleberg et al., 2010).
4. Conclusions
The purpose of this studywas to determine the feasibility of extend-
ing the previous study on fasted simulated intestinal media into fed
simulated intestinal media and determine any shifts in performance.
The results indicate that utilising a design of experiment technique is
feasible for the determination of equilibrium solubility and provides
data that is comparable inmagnitude and variability to literature results
in both HIF (Augustijns et al., 2014) and fed simulated intestinal media
(Clarysse et al., 2011). The information provides greater detail on the in-
teractions than previous approacheswhich have varied completemedia
or single components and has greater versatility than sampled HIF. The
technique provides a measure of the average solubility and variability
along with the importance of the media factors and factor interactions
which inﬂuence solubility.
The three drug groups acidic, basic and neutral display different pro-
ﬁles with respect to the most signiﬁcant factor and factors interactions
inﬂuencing solubility. For acidic drugs pH is dominant although with a
reduced margin and similar although fewer in number single factors
and interactions are present to those in the fasted DoE. Basic drugs fol-
low the same pattern in comparison to the fasted DoE as acidic drugs
and indicates that the surfactant components, especially oleate, bile
salt and lecithin are dominant over other factors (salt, buffer, pancrea-
tin) due to their higher concentration in fed simulated media. For neu-
tral drugs a more complex picture is evident with seven out of eight
single factors signiﬁcant plus over half of the possible interactions, indi-
cating that for these drugs solubilisation in fed simulated media is a
complex interplay. The DoE can also determine individual speciﬁc inter-
actions between drugs and media factors that do not follow the overall
trend within a group. Since pH is the predominant single factor
inﬂuencing solubility and in vivo pH is inﬂuenced by gastrointestinal
gas (Fiddiangreen et al., 1982) production and disposition (Mego et
al., 2015) the inﬂuence of carbon dioxide as a buffering system would
be an interesting experimental modiﬁcation. A number of factors were
not signiﬁcant or only had low impact for example pancreatin, salt
and buffer and in future studies these could be removed to limit the
number of experiments required or reduce the factors to increase detail.
A judicious approach would be required since pancreatin would be im-
portant for the performance of lipid based formulationswhere digestion
is important (Williams et al., 2012).
This DoE with ninety two experiments and the fasted with sixty six
is over one hundred and ﬁfty experiments somewhat larger than the
original goal of developing a technique suitable for 96 well plates
(Khadra et al., 2015). In future studies combining fed and fasted condi-
tions along with modiﬁcation of the DoE to only examine biorelevant
combinations will be required to meet this goal of describing a drug's
gastrointestinal solubility envelope in a single DoE. If this can be realised
then the measured maximum, minimum and average solubilities could
be applied to the Developability Classiﬁcation System (Butler and
Dressman, 2010) to provide a classiﬁcation range. In additionmeasured
intrinsic dissolution rates using the maximum, minimum and average
solubility simulated media could be applied to reﬁne PBPK models of
drug absorption (Kostewicz et al., 2014) permitting determination of
gastrointestinal content changes either through food intake or resulting
from transfer through the tract (Clarysse et al., 2009).
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